At Avacta we have developed Affimer® technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.
Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.
For further information see our website www.avacta.com
Unit 20 Ash Way
Thorp Arch Estate
Website: Avacta Life Sciences